Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo

Clinical Immunology

Volumn 151, Issue 1, 2014, Pages 29-42

  Regna, Nicole L ^a   Chafin, Cristen B ^a   Hammond, Sarah E ^a   Puthiyaveetil, Abdul G ^b   Caudell, David L ^c   Reilly, Christopher M ^a,d  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b AMERICAN UNIVERSITY OF RAS AL KHAIMAH   (United Arab Emirates)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Histone deacetylase; Regulatory T cells; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; GIVINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DEACETYLATION; DISEASE PREDISPOSITION; DRUG DOSE COMPARISON; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HISTONE ACETYLATION; HISTOPATHOLOGY; IMMUNE COMPLEX DEPOSITION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; IMMUNOREGULATION; IN VIVO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; REGULATORY T LYMPHOCYTE; SPLEEN WEIGHT; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH17 CELL;

HISTONE DEACETYLASE; REGULATORY T CELLS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACETYLATION; ANIMALS; ANTIBODIES, ANTINUCLEAR; BODY WEIGHT; CELL DIFFERENTIATION; DNA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; IMMUNOGLOBULIN G; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; PROTEINURIA; T-LYMPHOCYTE SUBSETS;

EID: 84893492404     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.01.002     Document Type: Article

References (64)

1. Aran A.A., Putterman C. Treatment of lupus nephritis: facing the era of immunotherapy. Panminerva Med. 2008, 50:235-245.
2. Mok C.C., Lau C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 2003, 56:481-490.
3. Kuhn A., Beissert S., Krammer P.H. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch. Dermatol. Res. 2009, 301:71-81.
4. Crispin J.C., Liossis S.N., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.T., Tsokos G.C. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 2010, 16:47-57.
5. Lee J.H., Wang L.C., Lin Y.T., Yang Y.H., Lin D.T., Chiang B.L. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006, 117:280-286.
6. Ryan M.J., McLemore G.R. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R736-742.
7. Perry D., Sang A., Yin Y., Zheng Y.Y., Morel L. Murine models of systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 2011:271694.
8. Benoist C., Mathis D., Satpathy A., Feuerer M. Survey of regulatory T cells (Treg) of the thymus and spleen in males of 33 inbred strains of mice, MPD:25804 2013, Mouse Phenome Database web site, The Jackson Laboratory.
9. Burnett R., Ravel G., Descotes J. Clinical and histopathological progression of lesions in lupus-prone (NZB×NZW) F1 mice. Exp. Toxicol. Pathol.: official journal of the Gesellschaft fur Toxikologische Pathologie 2004, 56:37-44.
10. Peutz-Kootstra C.J., de Heer E., Hoedemaeker P.J., Abrass C.K., Bruijn J.A. Lupus nephritis: lessons from experimental animal models. J. Lab. Clin. Med. 2001, 137:244-260.
11. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv. Immunol. 1985, 37:269-390.
12. Klinman D.M. IgG1 and IgG2a production by autoimmune B cells treated in vitro with IL-4 and IFN-gamma. J. Immunol. 1990, 144:2529-2534.
13. Puliaeva I., Puliaev R., Via C.S. Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE. Autoimmun. Rev. 2009, 8:219-223.
14. Crispin J.C., Kyttaris V.C., Terhorst C., Tsokos G.C. T cells as therapeutic targets in SLE, Nature reviews. Rheumatology 2010, 6:317-325.
15. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 2010, 28:445-489.
16. Mishra N., Reilly C.M., Brown D.R., Ruiz P., Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Investig. 2003, 111:539-552.
17. Sabry A., Sheashaa H., El-Husseini A., Mahmoud K., Eldahshan K.F., George S.K., Abdel-Khalek E., El-Shafey E.M., Abo-Zenah H. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 2006, 35:148-153.
18. Apostolidis S.A., Lieberman L.A., Kis-Toth K., Crispin J.C., Tsokos G.C. The dysregulation of cytokine networks in systemic lupus erythematosus. J. Interf. Cytokine Res.: the official journal of the International Society for Interferon and Cytokine Research 2011, 31:769-779.
19. Miyake K., Akahoshi M., Nakashima H. Th subset balance in lupus nephritis. J. Biomed. Biotechnol. 2011, 2011:980286.
20. Alunno A., Bartoloni E., Bistoni O., Nocentini G., Ronchetti S., Caterbi S., Valentini V., Riccardi C., Gerli R. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin. Dev. Immunol. 2012, 2012:823085.
21. Joshi S., Pantalena L.C., Liu X.K., Gaffen S.L., Liu H., Rohowsky-Kochan C., Ichiyama K., Yoshimura A., Steinman L., Christakos S., Youssef S. 1,25-Dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol. Cell. Biol. 2011, 31:3653-3669.
22. Apostolidis S.A., Crispin J.C., Tsokos G.C. IL-17-producing T cells in lupus nephritis. Lupus 2011, 20:120-124.
23. + bright T cells in peripheral blood of patients with primary Sjogren's syndrome. Lupus 2008, 17:34-39.
24. Wahl S.M., Chen W. Transforming growth factor-beta-induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Res. Ther. 2005, 7:62-68.
25. Wenzel J., Henze S., Brahler S., Bieber T., Tuting T. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Exp. Dermatol. 2005, 14:454-459.
26. Hayashi T., Hasegawa K., Adachi C. Elimination of CD4(+)CD25(+) T cell accelerates the development of glomerulonephritis during the preactive phase in autoimmune-prone female NZB×NZW F mice. Int. J. Exp. Pathol. 2005, 86:289-296.
27. Akimova T., Ge G., Golovina T., Mikheeva T., Wang L., Riley J.L., Hancock W.W. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin. Immunol. 2010, 136:348-363.
28. Beier U.H., Akimova T., Liu Y., Wang L., Hancock W.W. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr. Opin. Immunol. 2011, 23:670-678.
29. Yan K., Cao Q., Reilly C.M., Young N.L., Garcia B.A., Mishra N. Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. J. Biol. Chem. 2011, 286:28833-28843.
30. He H., Lehming N. Global effects of histone modifications. Brief. Funct. Genomics Proteomics 2003, 2:234-243.
31. Koarada S., Tada Y., Ushiyama O., Morito F., Suzuki N., Ohta A., Miyake K., Kimoto M., Nagasawa K. B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus. Arthritis Rheum. 1999, 42:2593-2600.
32. Reilly C.M., Regna N., Mishra N. HDAC inhibition in lupus models. Mol. Med. 2011, 17:417-425.
33. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3:166-179.
34. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nature Reviews. Cancer 2006, 6:38-51.
35. van Loosdregt J., Vercoulen Y., Guichelaar T., Gent Y.Y., Beekman J.M., van Beekum O., Brenkman A.B., Hijnen D.J., Mutis T., Kalkhoven E., Prakken B.J., Coffer P.J. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010, 115:965-974.
36. Lewis E.C., Blaabjerg L., Storling J., Ronn S.G., Mascagni P., Dinarello C.A., Mandrup-Poulsen T. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet beta cells in vivo and in vitro. Mol. Med. 2011, 17:369-377.
37. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409:581-589.
38. Matalon S., Palmer B.E., Nold M.F., Furlan A., Kassu A., Fossati G., Mascagni P., Dinarello C.A. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 2010, 54:1-9.
39. Furlan A., Monzani V., Reznikov L.L., Leoni F., Fossati G., Modena D., Mascagni P., Dinarello C.A. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 2011, 17:353-362.
40. Bodar E.J., Simon A., van der Meer J.W. Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes. Mol. Med. 2011, 17:363-368.
41. Glauben R., Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol. Med. 2011, 17:426-433.
42. Grabiec A.M., Korchynskyi O., Tak P.P., Reedquist K.A. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 2012, 71:424-431.
43. Leoni F., Fossati G., Lewis E.C., Lee J.K., Porro G., Pagani P., Modena D., Moras M.L., Pozzi P., Reznikov L.L., Siegmund B., Fantuzzi G., Dinarello C.A., Mascagni P. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 2005, 11:1-15.
44. Tan J., Cang S., Ma Y., Petrillo R.L., Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 2010, 3:5.
45. Vojinovic J., Damjanov N., D'Urzo C., Furlan A., Susic G., Pasic S., Iagaru N., Stefan M., Dinarello C.A. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011, 63:1452-1458.
46. Hayashi T., Hasegawa K., Sasaki Y., Mori T., Adachi C., Maeda K. Systemic administration of interleukin-4 expressing plasmid DNA delays the development of glomerulonephritis and prolongs survival in lupus-prone female NZB×NZW F1 mice. Nephrol. Dial. Transplant. 2007, 22:3131-3138.
47. Reilly C.M., Thomas M., Gogal R., Olgun S., Santo A., Sodhi R., Samy E.T., Peng S.L., Gilkeson G.S., Mishra N. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 2008, 31:123-130.
48. Nasu Y., Nishida K., Miyazawa S., Komiyama T., Kadota Y., Abe N., Yoshida A., Hirohata S., Ohtsuka A., Ozaki T. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthr. Cartil./OARS, Osteoarthritis Research Society 2008, 16:723-732.
49. Christensen D.P., Dahllof M., Lundh M., Rasmussen D.N., Nielsen M.D., Billestrup N., Grunnet L.G., Mandrup-Poulsen T. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med. 2011, 17:378-390.
50. Zhou X., Hua X., Ding X., Bian Y., Wang X. Trichostatin differentially regulates Th1 and Th2 responses and alleviates rheumatoid arthritis in mice. J. Clin. Immunol. 2011, 31:395-405.
51. Zhang H., Xiao Y., Zhu Z., Li B., Greene M.I. Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity. Immunol. Cell Biol. 2012, 90:95-100.
52. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
53. Kang H.K., Michaels M.A., Berner B.R., Datta S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J. Immunol. 2005, 174:3247-3255.
54. Paust H.J., Ostmann A., Erhardt A., Turner J.E., Velden J., Mittrucker H.W., Sparwasser T., Panzer U., Tiegs G. Regulatory T cells control the Th1 immune response in murine crescentic glomerulonephritis. Kidney Int. 2011, 80:154-164.
55. Cavassani K.A., Carson W.F.t., Moreira A.P., Wen H., Schaller M.A., Ishii M., Lindell D.M., Dou Y., Lukacs N.W., Keshamouni V.G., Hogaboam C.M., Kunkel S.L. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 2010, 115:4403-4411.
56. Zhou X., Kong N., Zou H., Brand D., Li X., Liu Z., Zheng S.G. Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity 2011, 44:43-50.
57. Saxena V., Lienesch D.W., Zhou M., Bommireddy R., Azhar M., Doetschman T., Singh R.R. Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J. Immunol. 2008, 180:1903-1912.
58. Grande J.P. Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus 1998, 7:604-610.
59. Strutz F., Neilson E.G. New insights into mechanisms of fibrosis in immune renal injury. Springer Semin. Immunopathol. 2003, 24:459-476.
60. Border W.A., Okuda S., Languino L.R., Sporn M.B., Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990, 346:371-374.
61. Hill G.S., Delahousse M., Nochy D., Thervet E., Vrtovsnik F., Remy P., Glotz D., Bariety J. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int. 2002, 61:2176-2186.
62. Filaci G., Bacilieri S., Fravega M., Monetti M., Contini P., Ghio M., Setti M., Puppo F., Indiveri F. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J. Immunol. 2001, 166:6452-6457.
63. Mohan C., Morel L., Yang P., Watanabe H., Croker B., Gilkeson G., Wakeland E.K. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J. Clin. Invest. 1999, 103:1685-1695.
64. Grabiec A.M., Krausz S., de Jager W., Burakowski T., Groot D., Sanders M.E., Prakken B.J., Maslinski W., Eldering E., Tak P.P., Reedquist K.A. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 2010, 184:2718-2728.